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The approval and subsequent wide-
spread clinical application of a diverse
array of new molecularly targeted anti-
cancer drugs over the last several years
has served to intensify the spotlight on
one of the most significant problems in
clinical oncology: acquired drug resis-
tance. This is especially true for tyrosine
kinase inhibitors such as imatinib
(Gleevec), which can induce striking
tumor responses in patients with chronic
myelogenous leukemia harboring the
bcr-abl translocation or in patients with
gastrointestinal sarcoma containing c-kit
mutations (Sawyers, 2005). Eventually,
however, this is followed by relapses
where the tumors are no longer respon-
sive to the drug. Such acquired resis-
tance is frequently the consequence of
the genetic instability of tumor cells 
and hence their mutational prowess
(Sawyers, 2005).
It is the cancer cell hallmark of genet-
ic instability that led to an often-cited the-
oretical advantage for developing and
using antiangiogenic drugs: lack of drug
resistance (Kerbel, 1991). Because the
drug target is a genetically stable normal
host cell, namely, the “activated” vascular
endothelium of a tumor’s growing neo-
vasculature, the initial assumption was
that such cells might not develop
acquired drug resistance in the way
tumor cells can.While a few early preclin-
ical studies seemed to support this
hypothesis, others suggested (Klement
Therapeutic implications of intrinsic or induced angiogenic growth
factor redundancy in tumors revealed
There is a large family of known proangiogenic growth factors, many of which can be expressed by a single tumor, espe-
cially in advanced stages of disease. Such redundancy, which can be amplified by hypoxia, has long been suspected as a
potential cause of acquired resistance when tumors are treated with highly specific targeted antiangiogenic drugs.
Definitive preclinical evidence for antiangiogenic drug evasion by alternate pathways of angiogenesis in tumor cells, likely
induced by antiangiogenic drug-mediated increases in tumor hypoxia, is reported in this issue of Cancer Cell (Casanovas
et al., 2005); it has major implications for the development of strategies to prolong the effectiveness of antiangiogenic
drugs as monotherapies, and for their use as chemosensitizing agents in combination treatment strategies.
Figure 1. A model for acquired resistance to a targeted antiangiogenic therapy
Schematic representation of some of the ways resistance can develop, in principle, to a targeted antiangiogenic drug in tumors which initially
respond to the drug, e.g., anti-VEGF or anti-VEGFR-2 antibody, as exemplified by the results of Casanovas et al. (2005). Angiogenesis in untreat-
ed tumors (A) is driven mainly, for example, by VEGF. Upon repetitive treatment with an agent such as an anti-VEGFR-2 antibody (B), some regres-
sion of newly formed immature tumor neovasculature (small red circles) occurs, and further angiogenesis is halted along with reduced
perfusion/flow in some remaining vessels, many of which are more mature, pericyte-covered vessels (larger red circles with a yellow border to
symbolize pericyte coverage), leading to a tumor response, e.g., a small reduction in tumor mass or no new growth (stable disease). The
aforementioned effects on the tumor vasculature lead to an overall increase in the levels of tumor hypoxia, which in turn leads to induction of
expression of new hypoxia-regulated proangiogenic growth factors, such as bFGF (C). The induction of bFGF induces angiogenesis in the face of
ongoing anti-VEGFR-2 therapy, leading to tumor relapse, i.e., resumption of angiogenesis and robust expansion of tumor mass (D). Initiation of
bFGF(R)-directed antiangiogenic therapy at this point could lead to angiogenesis inhibition once again and a tumor response (E). Eventually,
such a therapy could also fail over time due to such factors as: (1) induction of another functional proangiogenic growth factor, (2) increased
proportion of remodeled and mature (pericyte-covered) vessels, which are less responsive to antiangiogenic drugs in general, or (3) selection of
hypoxia-resistant tumor cell variants, which have a reduced dependence on tumor angiogenesis.
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et al., 2000) or showed (Yu et al., 2002)
otherwise, findings now ostensibly sup-
ported by clinical experience with the
anti-VEGF monoclonal antibody beva-
cizumab, the first approved antiangio-
genic drug for the treatment of cancer
(Hurwitz et al., 2004). This has spawned
a number of theories about the diverse
routes tumors can take to eventually
evade the effects of an antiangiogenic
drug treatment. These include mutation-
driven selection for hypoxia-resistant
tumor subpopulations that have a
reduced dependence on blood vessels
and oxygen for survival (Yu et al., 2002),
selection for more mature “remodeled”
stabilized blood vessels that are intrinsi-
cally less responsive to antiangiogenic
therapies (Glade Bender et al., 2004), or
redundancy of proangiogenic growth fac-
tors. This last cited mechanism is a con-
sequence of the well-known plethora of
proangiogenic growth factors expressed
by tumor cells (Kerbel and Folkman,
2002). A partial list of some of the better-
known ones include VEGF, bFGF (FGF-
2), angiopoietin-1, and probably
angiopoietin-2, IL-6, IL-8, placental
growth factor (PLGF), and PDGF, among
others. Consequently, the concern was
expressed many years ago that targeting
a single tumor cell-associated growth fac-
tor, or pathway, would likely lead to the
selection and outgrowth of subpopula-
tions producing alternative angiogenic
stimulators or pathways (See, for exam-
ple, Relf et al., 1997). This would be
especially true in late stage, advanced
cancers where the degree of such redun-
dancy appears to be substantially greater
than early stage disease (Relf et al.,
1997). Given the nature of cancer, the
logic of this type of drug resistance mech-
anism is compelling and probably
accounts for it being the most cited of all
theoretical mechanisms for acquired
resistance to antiangiogenic drugs
despite the fact that there was never any
direct definitive evidence for it – until now.
In this issue of Cancer Cell,
Casanovas et al. (2005) report a series
of elegant experiments to show that
specifically targeting the function of
tumor-associated VEGF leads to signifi-
cant tumor responses eventually fol-
lowed by tumor relapses in which
angiogenesis is apparently no longer dri-
ven by VEGF, but by an alternate path-
way (Figure 1). Mice with advanced
primary islet cell pancreatic carcinomas
were repeatedly treated with a mono-
clonal antibody to the major endothelial
cell signaling receptor tyrosine kinase
receptor for VEGF, called VEGFR-2 or
flk-1.VEGF is considered to be the major
proangiogenic factor for most forms 
of pathologic angiogenesis, including
tumor angiogenesis (Ferrara et al.,
2003). Indeed, it was previously reported
to be indispensable for growth of the
aforementioned tumor model based on
gene knockout studies (Inoue et al.,
2002). Thus, as expected, the tumors
responded and significant growth delays
(“stabilization”), or even regressions,
were observed. Eventually, however, the
tumors relapsed and started to grow
robustly, despite continued therapy dur-
ing which the ability of the drug to block
phosphorylation of VEGFR-2 was not
impaired, along with the maintenance of
VEGF expression in the tumors. This
was taken as evidence that another
proangiogenic pathway must be taking
over, thus making the VEGF/VEGFR-2
pathway dispensable. Indeed, a profiling
analysis revealed that several new
proangiogenic growth factors had
popped up in the relapsing tumors,
including bFGF and angiopoietin-1, and
even VEGF itself was elevated—all likely
consequences of increased levels of
tumor hypoxia induced by the initially
successful anti-VEGFR-2 treatment.
Evidence that bFGF was the main culprit
driving angiogenesis in the relapsing
tumors was shown by the fact that they
responded well to a therapy specifically
designed to target only bFGF receptors.
These results nicely complement a very
recent report by Mizukami et al. (2005)
who found that hypoxia-induced IL-8
tumor cell can compensate for partial
loss of VEGF and complete loss of HIF-
1, normally considered a major driver of
both VEGF and angiogenesis. Taken
together, these two studies suggest that
there are likely many alternative angio-
genic pathways that emerge after one
specific pathway is initially targeted in
tumors. The (first) one that arises will
likely depend on many factors, such as
tumor type, stage of disease, and the
nature of the therapy.
Aside from highlighting, in principle,
a mechanism for eventual evasion 
(resistance) to a therapy directed at the 
function of a specific proangiogenic 
factor—in this case VEGF—and an
approach to discover alternative targets
for antiangiogenic therapy, the results
would appear to bolster the rationale for
using drugs which selectively target
hypoxic tumor cells (Brown and Wilson,
2004) with antiangiogenic drugs, or alter-
natively, using multi-targeted antiangio-
genic receptor tyrosine kinase inhibitors
(RTKIs). With respect to the latter, multi-
targeted RTKIs, to varying degrees,
block phosphorylation of several different
tumor or endothelial cell associated
RTKs involved in promoting angiogene-
sis (Kerbel and Folkman, 2002). This
strategy, however, highlights several
ironies. First, the subject of the study by
Casanovas et al. concerns the develop-
ment of resistance to a targeted antian-
giogenic drug administered as a
monotherapy. But the major use and
successes of the antiangiogenic drug
approach in the clinic (up to this point at
least) have been when they are used in
combination with standard chemothera-
py regimens. This was first rigorously
established using a bevacizumab plus
standard chemotherapy combination in a
large randomized phase III clinical trials
of patient with advanced metastatic col-
orectal cancer (Hurwitz et al., 2004), but
has been duplicated more recently in
patients with advanced stage non-small
cell lung cancer, advanced metastatic
breast cancer, and refractory (second
line) colorectal cancer, as reported at
this year’s American Society for Clinical
Oncology (ASCO) annual meeting
(Marx, 2005). Strong signals indicating
the likelihood of similar combination
treatment successes to come in other
types of cancer, e.g., pancreatic cancer,
are evident from a variety of phase II tri-
als testing bevacizumab and chemother-
apy. So, it would appear that at least one
antiangiogenic drug, bevacizumab, may
turn out to be the most broadly generic
and effective chemosensitizing agent
available to delay acquired resistance to
chemotherapy.This is doubly ironic given
that antiangiogenics are usually consid-
ered to be “tumor starving” drugs that
compromise tumor blood flow and perfu-
sion—effects which would intuitively be
expected to diminish, rather than
enhance, the efficacy of chemothera-
py—all of which leads to the next irony,
namely, that so far, small molecule
antiangiogenic multi-targeted RTKIs
such as PTK787 have failed to demon-
strate the chemosensitizing ability of
antibodies, such as bevacizumab, in clin-
ical trials (Marx, 2005). Instead, the main
clinical successes of RTKIs developed to
inhibit angiogenesis have been as
monotherapies for a single cancer type,
renal cell carcinoma (Marx, 2005), where
the striking response rate results report-
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ed may be due to a variety of mecha-
nisms, not just inhibition of angiogenesis.
Given the fact that antiangiogenic
drugs are mainly used in combination
with chemotherapy, an obvious question
is whether relapses observed in patients
who are treated with a targeted drug
such as bevacizumab with chemothera-
py occur mainly as a consequence of
development of resistance to the target-
ed antiangiogenic drug in a manner simi-
lar to that described by Casanovas et al.,
or alternatively, to the chemotherapy
component of the regimen. If it is the for-
mer, the need for discontinuation of the
antiangiogenic drug therapy is obvious,
along with its possible replacement by
another drug that has a good chance of
showing resurrecting efficacy. If it is the
latter, continued use of the original
antiangiogenic drug and a change in
chemotherapy would be called for.
Considering the therapeutic conse-
quences of making the right (or wrong)
decision, as well as the enormous eco-
nomic implications, given the huge cost
of many new anti-cancer drugs, distin-
guishing between the two will obviously
assume an obvious degree of future
importance. Viewed from this perspec-
tive, the results of Casanovas et al., and
also of Mizukami et al. (2005) firmly
establish the multiplicity of compensato-
ry angiogenic pathways available to can-
cer cells as a likely cause of resistance
to specific targeted antiangiogenic
drugs, and suggest potential strategies
to delay such resistance, thus facilitating
not only their intrinsic antiangiogenic
properties, but their chemosensitizing
effects as well.
Robert S. Kerbel1,*
1Sunnybrook & Womens College Health
Sciences Centre and Department of 
Medical Biophysics, University of Toronto
*E-mail: robert.kerbel@swri.ca
Selected reading
Brown, J.M., and Wilson, W.R. (2004). Nat. Rev.
Cancer 4, 437–447.
Casanovas, O., Hicklin, D., Bergers, G., and
Hanahan, D. (2005). Cancer Cell, this issue.
Ferrara, N., Gerber, H.P., and LeCouter, J.
(2003). Nat. Med. 9, 669–676.
Glade Bender, J., Cooney, E.M., Kandel, J.J.,
and Yamashiro, D.J. (2004). Drug Resist. Updat.
7, 289–300.
Hurwitz, H., Fehrenbacher, L., Novotny, W.,
Cartwright, T., Hainsworth, J., Heim, W., Berlin,
J., Baron, A., Griffing, S., Holmgren, E., Ferrara,
N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F.
(2004). N. Engl. J. Med. 350, 2335–2342.
Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P.,
and Hanahan, D. (2002). Cancer Cell 1,
193–202.
Kerbel, R.S. (1991). Bioessays 13, 31–36.
Kerbel, R.S., and Folkman, J. (2002). Nat. Rev.
Cancer 2, 727–739.
Klement, G., Baruchel, S., Rak, J., Man, S.,
Clark, K., Hicklin, D., Bohlen, P., and Kerbel, R.S.
(2000). J. Clin. Invest. 105, R15–R24.
Marx, J. (2005). Science 308, 1248–1249.
Mizukami, Y., Jo, W.S., Duerr, E.M., Gala, M., Li,
J., Zhang, X., Zimmer, M.A., Iliopoulos, O.,
Zukerberg, L.R., Kohgo, Y., et al. (2005). Nat.
Med. 11, 992–997.
Relf, M., LeJeune, S., Scott, P.A., Fox, S., Smith,
K., Leek, R., Moghaddam, A., Whitehouse, R.,
Bicknell, R., and Harris, A.L. (1997). Cancer Res.
57, 963–969.
Sawyers, C.L. (2005). Nat. Med. 11, 824–825.
Yu, J.L., Rak, J.W., Coomber, B.L., Hicklin, D.J.,
and Kerbel, R.S. (2002). Science 295,
1526–1528.
DOI: 10.1016/j.ccr.2005.09.016
P R E V I E W S
This issue of Cancer Cell carries a report
of experiments with a mouse model of
the most common hereditary condition
facing the pediatric oncologist, neurofi-
bromatosis type 1 (NF1) (Chao et al.,
2005). Shannon and colleagues used
adolescent and young adult mice that
carry a mutation in Nf1, the gene respon-
sible for NF1, to study cancer resulting
from the effects of cytotoxic therapy in
genetically susceptible individuals. Mice
heterozygous for that mutation devel-
oped second malignant neoplasms
(SMNs) with or without the admin-
istration of radiation (RAD) and/or
chemotherapy with an alkylating agent
(cyclophosphamide [CY]) at a signifi-
cantly higher rate than wild-type controls
who were similarly treated (51/81 com-
pared to 17/100).
It was inevitable that I would be excit-
ed about this report, since the interaction
of therapy and genetic predisposition in
the etiology of SMNs has preoccupied
me during the past 30 years of my work
with survivors of childhood cancer.
During the decade of the 1970s, as it
became evident that children with cancer
would be able to survive for many years
after receiving treatment, concerns
began to be expressed regarding the
long-term effects of the RAD and
chemotherapy responsible for cure. With
colleagues at the National Cancer
Institute and three major pediatric oncol-
ogy centers, I embarked on a study of
late effects, especially SMNs, in sur-
vivors of childhood cancers.
Our report published in 1985 on the
spectrum of 308 SMNs in 292 childhood
cancer survivors seen at 13 institutions in
the United States, Canada, and Europe
noted that 68% had developed in a tissue
that had been exposed to RAD, that bone
and soft tissue sarcomas were the most
A mouse model for studying therapy-induced cancers
As more pediatric cancer patients survive for longer periods following treatment with cytotoxic agents, therapy-induced
second malignant neoplasms (SMNs) have become a major concern. In this issue of Cancer Cell, Chao et al. report that
mice carrying a mutation in Nf1, the gene responsible for neurofibromatosis type 1, treated with radiation and/or
cyclophosphamide, developed tumors similar to human SMNs at a significantly higher rate than did wild-type controls
treated similarly.This model provides efficient and rational means for testing procedures and agents that could inform clin-
icians regarding second cancer risks associated with treatment and, perhaps, reducing them.
